AnaptysBio, Inc. (ANAB): Price and Financial Metrics
ANAB Price/Volume Stats
| Current price | $19.83 | 52-week high | $27.50 |
| Prev. close | $21.47 | 52-week low | $13.36 |
| Day low | $19.79 | Volume | 363,855 |
| Day high | $21.78 | Avg. volume | 313,405 |
| 50-day MA | $23.31 | Dividend yield | N/A |
| 200-day MA | $20.07 | Market Cap | 530.71M |
ANAB Stock Price Chart Interactive Chart >
AnaptysBio, Inc. (ANAB) Company Bio
AnaptysBio Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. The company was founded in 2005 and is based in San Diego, California.
Latest ANAB News From Around the Web
Below are the latest news stories about ANAPTYSBIO INC that investors may wish to consider to help them evaluate ANAB as an investment opportunity.
AnaptysBio (NASDAQ:ANAB) shareholders have endured a 66% loss from investing in the stock five years agoOver the last month the AnaptysBio, Inc. ( NASDAQ:ANAB ) has been much stronger than before, rebounding by 50%. But... |
Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect?The consensus price target hints at a 69.4% upside potential for AnaptysBio, Inc. (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsAnaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolioIND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024Reiterating year-end 2023 cash and investments of $400 to $410 million and cash runway through year-end 2026 SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative |
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD DrugDespite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States. |
MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis StudyThough data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint. |
ANAB Price Returns
| 1-mo | -14.78% |
| 3-mo | -15.51% |
| 6-mo | 9.86% |
| 1-year | -13.33% |
| 3-year | -8.83% |
| 5-year | -73.20% |
| YTD | -7.42% |
| 2023 | -30.88% |
| 2022 | -10.82% |
| 2021 | 61.63% |
| 2020 | 32.31% |
| 2019 | -74.53% |
Continue Researching ANAB
Here are a few links from around the web to help you further your research on Anaptysbio Inc's stock as an investment opportunity:Anaptysbio Inc (ANAB) Stock Price | Nasdaq
Anaptysbio Inc (ANAB) Stock Quote, History and News - Yahoo Finance
Anaptysbio Inc (ANAB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...